Does Cannabis Support Synaptic Health in Dementia Patients?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Healthy brain function depends on strong connections between nerve cells, known as synapses. In dementia, these synaptic connections break down due to inflammation, oxidative stress, and the accumulation of abnormal proteins such as amyloid and tau. Researchers have therefore explored whether cannabinoids, active compounds in cannabis, could help protect or restore synaptic health.

However, according to NHS and NICE guidance, cannabis-based medical products are not recommended for treating dementia or improving brain cell connectivity because there is no proven clinical benefit (NHS Guidance; NICE NG144; NICE NG97).

What The Research Shows

Laboratory Evidence

Preclinical research suggests that cannabinoids may protect neurons and synapses in the brain by reducing inflammation and oxidative damage. Studies have found that activation of the CB1 and CB2 receptors in the endocannabinoid system (ECS) may help regulate neurotransmitter release and reduce toxic protein accumulation.

A 2024 Nature Reviews Neurology paper described these effects as potentially neuroprotective but emphasised that all findings are limited to cell and animal studies, not human trials (Nature Reviews Neurology, 2024).

A 2024 commentary from the Johns Hopkins Center for Psychedelic and Consciousness Research added that cannabinoids could theoretically stabilise synaptic activity through anti-inflammatory and antioxidant mechanisms, but that clinical validation is entirely lacking (Frontiers in Aging Neuroscience, 2024).

Human Clinical Trials

No human studies have shown improved synaptic health or brain connectivity in dementia patients treated with cannabis-based medicines.
A 2023 randomised trial of THC/CBD formulations in older adults with dementia found no measurable improvements in cognition, memory, or neural function, despite being well tolerated (PubMed Trial, 2023).
Systematic reviews from 2024 and 2025 reached the same conclusion: cannabinoids may modulate brain chemistry but do not prevent synaptic loss or cognitive decline (Meta-Analysis, 2024).

The Clinical Bottom Line

Cannabinoids may influence synaptic signalling in theory, but no human data show improved synaptic health.

Laboratory studies show potential neuroprotection that remains unproven clinically.

NICE, NHS, WHO, and Johns Hopkins researchers all conclude that evidence is preliminary.

Cannabis should not be used to treat dementia or prevent brain cell damage outside research trials.

Educational Context: AlleviMed

Educational organisations such as AlleviMed help patients understand how medical cannabis eligibility is assessed in the UK. They clarify that cannabis-based medicines are licensed only for a few specific conditions, such as severe epilepsy or multiple sclerosis, not for dementia or neuroprotection.

Takeaway

While cannabinoids appear to support synaptic function in laboratory experiments, no clinical studies confirm these effects in dementia. NHS, NICE, and Johns Hopkins experts all agree that cannabis-based products should not be used to preserve brain health outside formal, specialist-led research.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.